| Literature DB >> 29464430 |
Anna Tokar1, Jacqueline E W Broerse2, James Blanchard3, Maria Roura4,5.
Abstract
HIV testing uptake continues to be low among Female Sex Workers (FSWs). We synthesizes evidence on barriers and facilitators to HIV testing among FSW as well as frequencies of testing, willingness to test, and return rates to collect results. We systematically searched the MEDLINE/PubMed, EMBASE, SCOPUS databases for articles published in English between January 2000 and November 2017. Out of 5036 references screened, we retained 36 papers. The two barriers to HIV testing most commonly reported were financial and time costs-including low income, transportation costs, time constraints, and formal/informal payments-as well as the stigma and discrimination ascribed to HIV positive people and sex workers. Social support facilitated testing with consistently higher uptake amongst married FSWs and women who were encouraged to test by peers and managers. The consistent finding that social support facilitated HIV testing calls for its inclusion into current HIV testing strategies addressed at FSW.Entities:
Keywords: Female sex workers (FSWs); HIV diagnosis; HIV testing; Systematic review
Mesh:
Year: 2018 PMID: 29464430 PMCID: PMC6097720 DOI: 10.1007/s10461-018-2043-3
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Fig. 1PRISMA flow chart of citations
Overview of selected studies
| Study reference | Location | Study population (N, population group) | Study design | HIV testing uptake | Micro-level factors | |
|---|---|---|---|---|---|---|
| Barriers | Facilitators | |||||
| 1. Aho et al. [ | Guinea | N = 421 | Mixed (QN,CS & QL) | Ever tested:26.6% | n/a | Higher perceived risk |
| 2. Ameyan et al. [ | Ethiopia | N = 20 FSWs | QL | n/a | Lower perceived risk | Young age |
| 3. Batona et al. [ | Benin | N = 450 | QN,CS | Ever tested:87% | n/a | Previous testing |
| 4. Beattie et al. [ | India | N = 302 FSWs = 125 | QL | n/a | No ill health symptoms | Improved quality &duration of life (ART) |
| 5. Bengtson et al. [ | Kenya | N = 818 | QN, CS | Ever tested:88.6% Never tested:11% | 31 years and older | Having kids |
| 6. Burke et al. [ | Uganda | N = 88 | QL | n/a | n/a | n/a |
| 7. Chanda et al. [ | Zambia | N = 40 | QL | n/a | n/a | Pregnancy |
| 8. Chiao et al. [ | Philippines | N = 980 | QN, randomized quasi-experimental | n/a | n/a | Older age |
| 9. Dandona et al. [ | India | N = 6648 | QN,CS | Ever tested:7.9% | 16–17 years old | Engaged in SW > 5 years |
| 10. Deering et al. [ | Canada | N = 291 | QN,CS | Past year: 69.4% | n/a | n/a |
| 11. Deering et al. [ | Canada | N = 435 | QN,CS | Ever tested:87.4% | Migrant/new migrant | Older age of SW initiation |
| 12. Dugas et al. [ | Benin | N = 66 | QL | Every 6 months:46% | No symptoms | n/a |
| 13. Grayman et al. [ | Vietnam | N = 610 FSWs | QN,CS | Ever tested:30.9% | Never married | n/a |
| 14. Hong et al. [ | China | QN,CS | Ever tested:48% | Lower perceived risk | Higher HIV knowledge | |
| 15. King et al. [ | Russia | N = 29 | QL | Ever tested:100% | Drug use | Having money |
| 16. King et al. [ | Russia | N = 139 FSWs | QN,CS | n/a | Older age | n/a |
| 17. King et al. [ | Russia | N = 139 FSWs | Mixed (QN,CS& QL) | Ever tested: 97–100% | Drug use | Higher HIV knowledge |
| 18. Johnston et al. [ | Dominican Republic | N = 2781 | QN, CS | Past year: 16.6–30.8% | n/a | Higher HIV knowledge |
| 19. Ngo et al. [ | Vietnam | N = 30 FSWs (in-depth interview) | QL | n/a | Poor VCT knowledge | Fear of HIV |
| 20. Nhurod et al. [ | Thailand | N = 1006 FSWs | QN,CS | Acceptance:91.2% | n/a | n/a |
| 21. Park et al. [ | China | N = 348 | QN,CS | Past year:22% | n/a | Higher HIV knowledge |
| 22. Parriault et al. [ | Boarder between Brazil and French Guiana | N = 213 | QN, CS | Never tested: 31% | Older age | n/a |
| 23. Sayarifard et al. [ | Iran | N = 128 FSWs | QN,CS | Past year:25% | Poor knowledge | n/a |
| 24. Scorgie et al. [ | four countries of east and southern Africa (Kenya, Zimbabwe, Uganda and South Africa) | N = 106 FSWs N = 26 MSWs | QL | n/a | Poor VCT knowledge | n/a |
| 25. Shokoohi et al. [ | Iran | N = 1005 FSWs | QN, CS | Past year 27.5% | n/a | Older age at first SW |
| 26. Shokoohi et al. [ | Iran | N = 1337 | QN, CS | Ever tested:80.6% | n/a | Higher educational level |
| 27. Simonovikj et al. [ | Macedonia | N = 106 SWs | Case report | n/a | n/a | n/a |
| 28. Todd et al. [ | Uzbekistan | N = 448 FSWs | QN,CS | Ever tested:83.9% | Younger age | n/a |
| 29. Tran et al. [ | Vietnam | N = 1998 FSWs | QN,CS | Ever tested: 34.4% ESWs 24.4%-SSWs | Ever injected drugs | Duration of SW |
| 30. Wang et al. [ | China | N = 17 FSWs | QL | Willing:88% | Poor HIV knowledge (receiving information through TV on decrease of HIV P) | Higher risk awareness (receiving information through TV on increase of HIV P) |
| 31. Wang et al. [ | China | N = 970 | QN,CS | Willing:69% | n/a | Married |
| 32. Wang et al. [ | China | N = 970 | QN, Prospective cohort | Willing:69% | Lower perceived risk | Engaged in SW > 12 months |
| 33. Wanyenze et al. [ | Uganda | QL | n/a | Poor HIV knowledge | n/a | |
| 34. Wilson et al. [ | Australia | N = n/a | Mathematical model | n/a | n/a | n/a |
| 35. Xun et al. [ | China | N = 371 MSM | QN,CS | Willing:72.1% | n/a | Willing to pay 4.8 USD for oral test |
| 36. Xu et al. [ | China | N = 164 | QN | Ever tested:32.1%-HIV+ , 16.1%-HIV− | n/a | More than 9 years of schooling |
ART antiretroviral therapy, CS cross sectional, EES entertainment-based sex workers, FGDs focus group discussions, FSWs female sex workers, HC health care, HCWs healthcare workers, HIV human immunodeficiency virus, HIV P HIV prevalence, HR harm reduction, IDUs injection drug users, ID identity card, MSM men who have sex with men, MSWs male sex workers, NGO non-governmental organizations, SP sexual partner, STI sexually transmitted infections, SSWs street-based sex workers, SW sex work, TSG transgender, QN quantitative, QL qualitative, n/a non applicable, VCT voluntary counselling and testing
Fig. 2Conceptual framework: barriers and facilitators of HIV testing amongst FSWs.
Reproduced with Permission from Blanchard et al. [22]
| HIV (human Immunodeficiency virus) | HIV testing/test/tested | Sex work |
|---|---|---|
| OR acquired immunodeficiency syndrome OR AIDS | OR voluntary counselling and testing OR VCT | OR people who sell sex |
| OR HIV | OR provider initiated testing and counselling OR PITC | OR sex industry/sex business |
| OR provider initiated counselling and testing OR PICT | OR prostitution | |
| OR diagnostic/diagnosed | OR FSW OR female sex workers | |
| OR screening/screened | OR CSW OR commercial sex workers | |
| OR routine testing, Opt-In, Opt-Out | OR sex services | |
| OR positive result | OR escort services | |
| OR testing and counselling OR HTC | OR paid sex | |
| OR transactional sex |
| Title |
| Date published |
| Date of research |
| Authors |
| Study design |
| Research objectives/research questions |
| Country |
| Study population |
| Main methods of research |
| Main results |
| Main conclusions |
| Comments*(if needed) |
Quality assessment of the 36 studies
| Study reference | Study design | Summary score for quality assessment |
|---|---|---|
| Qualitative methods (Spencer et al. [ | ||
| Ameyan et al. [ | QL | 61% (11/18) |
| Beattie et al. [ | QL | 72% (13/18) |
| Burke et al. [ | QL | 61% (11/18) |
| Chanda et al. [ | QL | 67% (12/18) |
| Dugas et al. [ | QL | 50% (9/18) |
| King et al. [ | QL | 50% (9/18) |
| Ngo et al. [ | QL | 72% (13/18) |
| Scorgie et al. [ | QL | 67% (12/18) |
| Wang et al. [ | QL | 67% (12/18) |
| Wanyenze et al. [ | QL | 72% (13/18) |
| Quantitative methods (modified Downs and Black [ | ||
| Batona et al. [ | QN | 56% (14/25) |
| Bengtson et al. [ | QN | 52% (13/25) |
| Chiao et al. [ | QN | 72% (18/25) |
| Dandona et al. [ | QN | 40% (10/25) |
| Deering et al. [ | QN | 60% (15/25) |
| Grayman et al. [ | QN | 48% (12/25) |
| Hong et al. [ | QN | 52% (13/25) |
| Johnston et al. [ | QN | 64% (16/25) |
| King et al. [ | QN | 52% (13/25) |
| Nhurod et al. [ | QN | 56% (14/25) |
| Parriault et al. [ | QN | 36% (9/25) |
| Shokoohi et al. [ | QN | 56% (14/25) |
| Shokoohi et al. [ | QN | 60% (15/25) |
| Todd et al. [ | QN | 52% (13/25) |
| Tran et al. [ | QN | 52% (13/25) |
| Wang et al. [ | QN | 48% (12/25) |
| Wang et al. [ | QN | 48% (12/25) |
| Wilson et al. [ | QN, mathematical modeling | n/a |
| Xun et al. [ | QN | 56% (14/25) |
| Xu et al. [ | QN | 64% (16/25) |
| Mixed methods (modified Downs and Black [ | ||
| Aho et al. [ | QN & QL | 68% (17/25) |
| King et al. [ | QN & QL | 48 (12/25) |
| Abstracts | ||
| Deering et al. [ | QN | n/a |
| Park et al. [ | QN | n/a |
| Sayarifard et al. [ | QN | n/a |
| Simonovikj et al. [ | Case report | n/a |
QL qualitative, QN quantitative
| Section/topic | # | Checklist item | Reported (Yes/No) |
|---|---|---|---|
| Title | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | Yes |
| Abstract | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | Yes |
| Introduction | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | Yes |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | Not applicable |
| Methods | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | Not available |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | Yes |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | Yes |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Yes (“ |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | Yes (Fig. |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | Yes (“ |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | Yes |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | Not available |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | Yes |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | Not applicable |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | Yes |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | Not available |
| Results | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | Yes (Fig. |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Yes (Table |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | Not available |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | Not applicable |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | Not applicable |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | Yes |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | Not available |
| Discussion | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | Yes (Table |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | Yes |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | Yes |
| Funding | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | Not available |